ライフサイエンスコーパス: specific inhibitor

1 signaling pathway by ruxolitinib, a JAK-STAT-specific inhibitor.

2 juxtamembrane region occurs in trans using a specific inhibitor.

3 or by inhibiting its kinase activity using a specific inhibitor.

4 ave built a pharmacophore model for a CYP3A4-specific inhibitor.

5 were decreased by omega-conotoxin, a Cav2.2-specific inhibitor.

6 of SphK1 was assessed using siSphK1 or SphK-specific inhibitor.

7 verted by the addition of Sfrp1 or an ADAM10-specific inhibitor.

8 than 1,10-phenanthroline, a metalloprotease-specific inhibitor.

9 activity is controlled by calpastatin, their specific inhibitor.

10 occal disease in patients treated with an AP-specific inhibitor.

11 itional point of binding for a fungal enzyme-specific inhibitor.

12 However, screens have yielded only a few specific inhibitors.

13 nositol 3-kinase inhibitors or PI3Kp110alpha-specific inhibitors.

14 e of MAB_4780 opens the way to identify such specific inhibitors.

15 o conflicting reports and lack of potent and specific inhibitors.

16 n delta-1 S268, which was reversible by mTOR-specific inhibitors.

17 r findings may facilitate the development of specific inhibitors.

18 es bearing distinct fluorophores and subunit-specific inhibitors.

19 bithionol and hexachlorophene as potent, sAC-specific inhibitors.

20 s opportunities for targeted treatment using specific inhibitors.

21 ls were, in contrast, more sensitive to JAK3-specific inhibitors.

22 mer-dependent acquired resistance to monomer-specific inhibitors.

23 ylyl cyclase (sGC) or adenylate cyclase (AC) specific inhibitors.

24 be further exploited in the design of CA IX-specific inhibitors.

25 along with an overview of the development of specific inhibitors.

26 d-gain of function assays, and in vivo using specific inhibitors.

27 of SphK inhibitors including SphK1 and SphK2 specific inhibitors.

28 they are promising targets for the design of specific inhibitors.

29 al parameters for the design of conformation-specific inhibitors.

30 d there exist no effective global or isoform-specific inhibitors.

31 g pathways of IL-12 were determined by using specific inhibitors.

32 rest in the development of new efficient and specific inhibitors.

33 ble efficacy and safety profile of this JAK3-specific inhibitor 11 led to its evaluation in several h

34 We found that the IRE1a-specific inhibitor 4mu8C could suppress the production o

35 Treatment with the Bcl-xL-specific inhibitor, A-1331852, reduces liver fibrosis, p

36 Targeting BCL2 by the specific inhibitor ABT-199 synergized with ibrutinib in

37 ar requirements for the design of potent and specific inhibitors against flaviviral proteins will con

38 was also significantly inhibited by an AURKA specific inhibitor, alisertib (MLN8237).

39 A or blocking the downstream signalings with specific inhibitors also demonstrated a suppression of t

40 inhibition of CARM1 activity with the CARM1-specific inhibitor AMI-1 significantly increased spine w

41 Studies with an AKT2-specific inhibitor and cells isolated from WT and Akt KO

42 Using Rac1-specific inhibitor and dominant-negative mutant N17Rac1,

43 Using a PADI1-specific inhibitor and Padi1-morpholino knockdown, we fo

44 Both PLC-gamma1-specific inhibitor and short hairpin RNA (shRNA) strongl

45 glomerular permeability; additionally, using specific inhibitors and activators of TRPC6, we showed t

46 ogesterone (P4)-induced AR by using a set of specific inhibitors and knock-out mice.

47 the proteasome to the point of toxicity with specific inhibitors and performed genome-wide screens fo

48 Using specific inhibitors and quantitative analysis at the sin

49 gned two classes of M2-S31N inhibitors, S31N-specific inhibitors and S31N/WT dual inhibitors, which a

50 Specific inhibitors and short hairpin RNA (shRNA) were e

51 Here, we describe the identification of TrkA-specific inhibitors and the structural basis for their s

52 Signaling study with specific inhibitors and Western blot analysis demonstrat

53 Blocking these pathways with specific inhibitors and/or genetic modifications signifi

54 s was confirmed in co-culture by using their specific-inhibitors and exogenous recombinant-proteins.

55 However, when GzmB and GzmB-specific inhibitor are both provided to the cocultures,

56 Studies with more potent and specific inhibitors are needed to establish any potentia

57 potential drug targets, but their potent and specific inhibitors are not available, and strategies fo

58 ntain overactive CDK4/6-cyclin D, and CDK4/6-specific inhibitors are promising anti-cancer therapeuti

59 olymer conjugate (an iBody) containing a FAP-specific inhibitor as the targeting ligand.

60 itination in HSC signaling, and point to DUB-specific inhibitors as reagents to expand stem cell popu

61 Thus, inhibition of FAK/PI3K activities by specific inhibitors as well as short-hairpin RNA downreg

62 cable for the development of other substrate-specific inhibitors as well.

63 s to CC in vitro using recombinant proteins, specific inhibitors, as well as deficient and normal ser

64 ion of DIO2 by FOXO1 was confirmed using its specific inhibitor AS1842856 or adenoviral infection of

65 Targeting SMYD2 with its specific inhibitor, AZ505, delayed cyst growth in both e

66 ellular carcinoma, administration of the GLS-specific inhibitor bis-2-(5-phenylacetamido-1,3,4-thiadi

67 ng and blockage of the GABAA receptor by the specific inhibitors both significantly impaired arboviru

68 Blockade of NKCC1 after SE with the specific inhibitor bumetanide restored NKCC1 and KCC2 ex

69 and biological effects of ACY-1215, an HDAC6-specific inhibitor, by using murine CD8 T cell-related s

70 The p110delta-specific inhibitor, Cal-101, and small interfering RNA-m

71 hese findings suggest that transamidase site-specific inhibitors can inhibit GTP binding/signalling b

72 Inhibition of Arp2/3 through a specific inhibitor, CK548, also drastically inhibited HI

73 ctive benzimidazole-derived CK1delta/epsilon-specific inhibitor compound with significant effects on

74 t chemically perturbing Fus3 dynamics with a specific inhibitor could effectively redirect the mating

75 This effect was abrogated by the PDGFRalpha-specific inhibitor crenolanib.

76 sion and cell migration, whereas a miR-95-3p specific inhibitor decreased cell proliferation, cell cy

77 phospho-site mutation and treatment with CK2 specific inhibitors demonstrated that phosphorylation at

78 Inhibition of CAMKIIgamma with a specific inhibitor destabilized c-Myc and reduced tumor

79 Given the importance of specific inhibitor development, it is crucial to underst

80 ubstitute AMP1 in planta and that an HsGCPII-specific inhibitor does not evoke amp1-specific phenotyp

81 nt of vhl(-/-) mutant embryos with HIF2alpha-specific inhibitors downregulated Hif target gene expres

82 Degradation of miR-650 by specific inhibitor dramatically increased the expression

83 were modified by adding exogenous enzyme or specific inhibitors during the milling and subsequent kn

84 from the covalent binding of the proteasome-specific inhibitor epoxomicin to BPH.

85 Moreover, the Epac-specific inhibitor ESI-09 inhibits established CFA-induc

86 armacologic inhibition of Epac1 with an Epac specific inhibitor, ESI-09, phenocopied the effects of E

87 hibited in PK-15 cells treated with U0126, a specific inhibitor for MEK1/2/ERK1/2, whereas MEK2 did n

88 We also present felodipine as a specific inhibitor for oncogenic Aurora A kinase.

89 id cancer cells; so, we explore bosutinib, a specific inhibitor for SRC, to explore SRC as a mediator

90 We used this cocktail to develop specific inhibitors for beta1c, beta2c, beta5c, and beta

91 Specific inhibitors for ERK1/2 MAPK (PD98059), p38 MAPK

92 inated by PD98059, BI-D1870, or sc68376, the specific inhibitors for Erk1/2, p90RSK, or p38, respecti

93 n serve as a starting point in the design of specific inhibitors for GLUT5.

94 ive of approaches to develop IRAK1- or IRAK4-specific inhibitors for potential therapeutic applicatio

95 ic rationale for the development of PI3Kbeta-specific inhibitors for the treatment of PTEN-deficient

96 C1/2 kinase inhibitors and developing mTORC2-specific inhibitors for use in this setting.

97 ecies (ROS) production by using the isoprene specific inhibitor fosmidomycin, acute O3 exposure (300

98 PT2385, a HIF-2alpha-specific inhibitor, had preventive and therapeutic effec

99 ttractive target for cancer therapy, but few specific inhibitors have been found.

100 Mechanistic target of rapamycin (mTOR)-specific inhibitors have been previously assessed but th

101 and exceeded cell killing by the PI3K-delta-specific inhibitor idelalisib.

102 Furthermore, the PI3K p110delta-specific inhibitor, idelalisib, also demonstrates activi

103 tion of P300 acetyltransferase activity by a specific inhibitor improves insulin sensitivity and decr

104 ancy was assessed using celecoxib as a COX-2 specific inhibitor in a murine model of OSA bearing Lewi

105 nes acting as a new class of bacterial betaG-specific inhibitors in a pH-dependent manner.

106 ion is primarily handled by SGLT2, and SGLT2-specific inhibitors, including dapagliflozin, canagliflo

107 tly controlled by a limited number of tissue-specific inhibitors, including SPINK6, an inhibitor of t

108 sm by talarozole, a cytochrome P450 (CYP) 26 specific inhibitor, increased the effects ofatRA on mito

109 as early as 4 h upon exposure and the use of specific inhibitors indicated the involvement of ADAM10/

110 rlaps with the pocket occupied by some H3 HA-specific inhibitors, indicating the high relevance of th

111 se 2 (JAK2)/STAT3 and TGF-beta1 signaling by specific inhibitors inhibited BMF-induced sphere formati

112 However, recent entry of pathway-specific inhibitors into the clinic reveals mixed patien

113 ebsiella pneumoniae carbapenemases (KPC), no specific inhibitor is available for the phenotypic detec

114 research interest in identifying potent CK1-specific inhibitors is still increasing.

115 ide hydroxamic acid (SAHA) and a novel HDAC6-specific inhibitor (KA1010) in models of alloreactivity.

116 dium phosphatidylinositol-4-OH kinase (PI4K)-specific inhibitor KDU691.

117 The sAC-specific inhibitor KH7 not only reversed sensitization t

118 The specific inhibitor (Ly294002) of PI3K/AKT pathway signif

119 CDK9 specific inhibitors may be a potential alternative treat

120 ithelial cell lines incubated with the DNM1L-specific inhibitor Mdivi-1.

121 s G121-treated human DCs was blocked by TLR8-specific inhibitors, mediated by L lactis G121 RNA, and

122 itutively active) Akt and reduced by the Akt-specific inhibitor MK2206.

123 lung-specific inhibition of iNOS with a iNOS-specific inhibitor, N6-(1-iminoethyl)-L-lysine, dihydroc

124 on and tested the utility of two novel KDM1A-specific inhibitors (NCL-1 and NCD-38) to promote differ

125 COX-1/2 inhibitor indomethacin and the COX-2-specific inhibitors NS-398 and celecoxib or siRNAs targe

126 or survival of Tmem in chronic infection, a specific inhibitor of acetyl CoA carboxylase 1, 5-(tetra

127 tly abrogated in the presence of PD146176, a specific inhibitor of ALOX15.

128 stration of low-dose carboxyatractyloside, a specific inhibitor of ANT.

129 ification of BRD-7880 as a potent and highly specific inhibitor of aurora kinases B and C.

130 clic diterpenoid aphidicolin is a potent and specific inhibitor of B-family DNA polymerases, halterin

131 FH535, a specific inhibitor of beta-catenin signaling, reduced th

132 at co-administration of a cyclic RGD-mimetic-specific inhibitor of beta3 integrin significantly atten

133 Calpastatin is an endogenous specific inhibitor of calpain, a calcium-dependent cyste

134 , our results strongly suggest that LF3 is a specific inhibitor of canonical Wnt signaling with antic

135 ar properties, thus questioning its use as a specific inhibitor of cargo recognition by the AP-2 adap

136 XIAP) is the most potent naturally occurring specific inhibitor of caspase-3.

137 ither with Ser-to-Ala substitution or with a specific inhibitor of CDK4/6 kinase blocked Her4-induced

138 slices and MDCK-AQP2 cells, R-roscovitine, a specific inhibitor of cdks, increased pS256 levels and d

139 ell cycle regulator of NHEJ) is a cell-cycle-specific inhibitor of cNHEJ.

140 2,3-dioxygenase (IDO), but not by NSC-398, a specific inhibitor of COX-2, suggesting IDO as a mediato

141 tably enhanced in the presence of MLN4924, a specific inhibitor of cullin-RING E3 ligases.

142 ipumps were used to infuse intracerebrally a specific inhibitor of depolarizing GABAergic transmissio

143 ce with tauroursodeoxycholic acid (TUDCA), a specific inhibitor of ER stress.

144 A specific inhibitor of extracellular PPIA, MM218, given a

145 Infusion of a specific inhibitor of Fn-EDA into Apoe(-/-) mouse 15 min

146 differentiation assays of naive T cells with specific inhibitor of Foxo1 or inhibitors of the PI3K/Ak

147 dy identifies and characterizes the tightest specific inhibitor of Grb7 to date, representing a signi

148 eening excise, we showed that netropsin, the specific inhibitor of HMGA2-DNA interactions, strongly i

149 d production of IL-6 and coproduction of the specific inhibitor of IL-6 trans-signaling, human sgp130

150 y pretreatment with 1-methyl-D-tryptophan, a specific inhibitor of indoleamine-pyrrole 2,3-dioxygenas

151 F4G-eIF3 interactions converted eIF4E into a specific inhibitor of initiation on capped mRNAs.

152 beneficial therapeutic effect of AZD1480, a specific inhibitor of JAK1/2, in suppressing neuroinflam

153 of the oxazolidinone GSK180 as a potent and specific inhibitor of KMO.

154 As a specific inhibitor of Lp-PLA2, darapladib has been shown

155 A specific inhibitor of MDA-9/Syntenin activity, PDZ1i (11

156 The presence of a specific inhibitor of MMP activity was sufficient to res

157 sent study investigated whether rapamycin, a specific inhibitor of mTOR, ameliorates inflammatory str

158 sue, we examined the effects of rapamycin, a specific inhibitor of mTOR, on B cell and CD4 T cell res

159 ell accumulation were reversed by IDH-C35, a specific inhibitor of mutant IDH1.

160 Ouabain (10 mumol l(-1)), a specific inhibitor of Na/K-ATPase, abolished dopamine-in

161 Injecting Atm-null mice with fulvene-5, a specific inhibitor of NOX4 and NADPH oxidase 2 (NOX2), d

162 ithout or with thiamet-G (TMG), a potent and specific inhibitor of O-GlcNAcase.

163 IQ-1, a specific inhibitor of p300/beta-catenin interaction, pre

164 ticular chondrocytes, in vitro, with IOX2, a specific inhibitor of PHD2, promoted articular chondrocy

165 oughput screening technique, we identified a specific inhibitor of phosphatase of regenerating liver

166 LY294002, a specific inhibitor of phosphatidylinositol-3-kinase (PI3

167 of zeta inhibitory peptide (ZIP), a supposed specific inhibitor of PKMzeta that interferes with both

168 athway, using GEF-dead mutants of Trio and a specific inhibitor of Rac1 activation by Trio.

169 inistration of the drug trametinib, a highly specific inhibitor of Ras-Erk-ETS signaling, can extend

170 e dihydroxycoumarin compound F3284-8495 as a specific inhibitor of RT RNase H, with low micromolar po

171 Mithramycin A, a specific inhibitor of Sp1 oligonucleotide binding, and S

172 Fatostatin was recently discovered as a specific inhibitor of SREBP cleavage-activating protein

173 t the addition of 500 ppm lactisole, a human-specific inhibitor of STRs.

174 t regulates H3K9me3 (using a newly developed specific inhibitor of SUV39H1), it is possible to alter

175 njected with (5Z)-7-oxozeaenol, a potent and specific inhibitor of TAK1.

176 We found that Compound II is a potent and specific inhibitor of TBK1-mediated IFN response.

177 ection of compounds and identified ABT263 (a specific inhibitor of the anti-apoptotic proteins BCL-2

178 sting that treatment of this type of HX by a specific inhibitor of the Gardos channel could be consid

179 Here we demonstrate that GSK-J4, a specific inhibitor of the H3K27me3 histone demethylases

180 hereas the effect of eATP was inhibited by a specific inhibitor of the P2X7 receptor (P2X7R).

181 F-beta signaling, we used SB431542 (SB43), a specific inhibitor of the TGF-beta type I receptor Alk4/

182 l-trans-retinylamine (Ret-NH2), a potent and specific inhibitor of the trans-to-cis reisomerization r

183 Tubacin, a specific inhibitor of the ubiquitin-binding, proautophag

184 circulating levels of Dickkopf-1 (DKK-1), a specific inhibitor of this pathway, are altered in patie

185 associated kinase-M (IRAK-M) is a macrophage-specific inhibitor of Toll-like receptor (TLR) and IL-1

186 The specific inhibitor of trypsin, N-alpha-p-tosyl-L-lysine

187 of partial pressure of CO2 Bafilomycin A1, a specific inhibitor of vacuolar-type H(+)-ATPase that blo

188 We describe a new neuron-specific inhibitor of viral infections in the central ne

189 In our effort to discover potent and specific inhibitors of 17alpha-hydroxylase/17,20-lyase (

190 port the development of the first potent and specific inhibitors of a single Eph isoform, EphB3.

191 Ceapins are highly specific inhibitors of ATF6alpha signaling, not affectin

192 However, there are currently no specific inhibitors of autophagy.

193 These effects were abolished by specific inhibitors of both pathways, demonstrating that

194 use of beta-lactones, which remain the only specific inhibitors of ClpP discovered to date.

195 Specific inhibitors of COX-2 and 5-LOX decreased formati

196 ibitors as well as prioritize novel, context-specific inhibitors of difficult targets, such as MYC an

197 will discuss possibilities to develop highly specific inhibitors of FGF2 secretion, a novel approach

198 lades B4 and B1 and should help in designing specific inhibitors of gelatin degradation.

199 oth MPA and mycophenolate mofetil are highly specific inhibitors of guanine nucleotide synthesis and

200 Here we report that specific inhibitors of Hsp90 such as 17-(N-allylamino)-1

201 tions allowed the identification of cofactor-specific inhibitors of InhA that do not require activati

202 n B lymphocytes latently infected with KSHV, specific inhibitors of KSHV miR-K9 led to increased GADD

203 t surface display technique to obtain highly specific inhibitors of MMP-14 by modifying the natural n

204 pe and drug-resistant Mtb strains identified specific inhibitors of Mtb ADK with micromolar antimycob

205 Intestine-specific inhibitors of MTP decrease chylomicron biogenes

206 oited therapeutically through development of specific inhibitors of MUS81 nuclease activity.

207 evasion in IDH-MUT gliomas and suggest that specific inhibitors of mutant IDH may improve the effica

208 Here we develop specific inhibitors of polyphosphate and show that this

209 microRNAs (miRNAs) are sequence-specific inhibitors of post-transcriptional gene express

210 y in clinical use, and recent development of specific inhibitors of protein-arginine deiminase 4 (PAD

211 Na(+)-coupled glucose transporter SGLT2, and specific inhibitors of SGLT2 are now available to patien

212 Our findings suggest that parasite-specific inhibitors of SUMOylation could be developed an

213 potential target for development of parasite-specific inhibitors of SUMOylation.

214 and these can be exploited for the design of specific inhibitors of T4SS function.

215 (HPV) and E1A from adenovirus, as potent and specific inhibitors of the cGAS-STING pathway.

216 st-translocation complexes were sensitive to specific inhibitors of the eukaryotic ribosome, demonstr

217 es YM-254890 and FR900359 are the only known specific inhibitors of the Gq subfamily of G proteins; h

218 Nedd4, Mule/Huwe1, and WWP1, and thus act as specific inhibitors of these enzymes in vitro.

219 rpigmentation phenotype can be rescued using specific inhibitors of these signaling pathways.

220 e not well defined partly due to the lack of specific inhibitors of this complex cellular process.

221 The design of potent and specific inhibitors of this enzyme will be essential to

222 Specific inhibitors of this pathway have been keenly res

223 en-activated protein kinase pathway, whereas specific inhibitors of this pathway reduced macrophage p

224 yl)phenol compounds described by Kategaya as specific inhibitors of USP7.

225 yet little is known about the innate neuron-specific inhibitors of viral infections in the CNS.

226 that breast tumors treated with a p110alpha-specific inhibitor often circumvent inhibition and resum

227 fects of rapamycin and an S6 kinase 1 (S6K1)-specific inhibitor on T cell activation and proliferatio

228 d by directly inhibiting its activity with a specific inhibitor or/and by preventing its maturation.

229 In contrast, inhibition of HER1 using specific inhibitors or decreasing expression of HER3 or

230 n regulation of striatal output using either specific inhibitors or PDE10A knock-out mice and has bee

231 reatment with a pan-HDAC inhibitor, an HDAC6-specific inhibitor, or depletion of HDAC6, suggesting th

232 Inhibition of STAT3 by Stattic, a STAT3-specific inhibitor, or STAT3-specific siRNA sensitized r

233 e CDK4/6 pathway and responses to the CDK4/6-specific inhibitor palbociclib.

234 cked deacetylation of ac-SMC3 using an HDAC8-specific inhibitor PCI-34051 in MCF7 breast cancer cells

235 ne deacetylase 8 (HDAC8) by either the HDAC8-specific inhibitor PCI-34051 or small interference (si)R

236 HDAC8 by small interfering RNAs or the HDAC8-specific inhibitor PCI-34051, respectively, induced expr

237 s cell division arrest induced by the CDK4/6-specific inhibitor PD-0332991.

238 /Tau) mutant SCN treated with the CK1epsilon-specific inhibitor PF-4800567 (3-[(3-Chlorophenoxy)methy

239 The p53-specific inhibitor pifithrin-alpha (PFT-alpha) significa

240 PI4KA-specific inhibitors promote replication of unadapted vir

241 nt on reversible binding of glucokinase to a specific inhibitor protein, glucokinase regulatory prote

242 m that allows cancer cells to evade oncogene-specific inhibitors, providing a rationale to cotarget E

243 analysis of rice cells treated with the TOR-specific inhibitor rapamycin revealed that TOR not only

244 or AZD8055, in contrast to allosteric mTORC1-specific inhibitor rapamycin, strongly inhibited 4E-BP1

245 Although its specific inhibitor, rapamycin, is currently used as an i

246 er, we were surprised that transamidase site-specific inhibitors reduce cancer stem cell survival.

247 inhibition of ERK1/2 phosphorylation with a specific inhibitor reduced the activation of ROCK1.

248 ockdown of PRMT5 or inhibition of PRMT5 by a specific inhibitor reduces the expression of AR and supp

249 and pre-treatment with a p44/42 ERK pathway-specific inhibitor, resulted in a complete inhibition of

250 of known regulators of TAZ degradation using specific inhibitors revealed a role for heat shock prote

251 nhibition of topoisomerase II activity using specific inhibitors revealed quite dramatic effect on co

252 n gingipain production, along with gingipain-specific inhibitors, revealed that gingipain proteolytic

253 ed cell cultures, STAT3 suppression with the specific inhibitor S3I-201 attenuated GH transcription a

254 type mouse or human platelets with the Vps34-specific inhibitors, SAR405 and VPS34-IN1, induced abnor

255 endothelial cells in the presence of the p38-specific inhibitor SB 202190 revealed that inhibition of

256 Blockade of the TGF-beta pathway with the specific inhibitor SB431542 and via SMAD-3 siRNA prevent

257 inhibitors and found that ABT-199 (the BCL-2 specific inhibitor) selectively killed pDCs but not cDCs

258 We propose that development of CARM1-specific inhibitors should focus on its N-terminus and p

259 Blockade of p75 cleavage using a specific inhibitor significantly improves migration and

260 kade of JAK2/STAT3 and TGF-beta signaling by specific inhibitors significantly inhibited cell prolife

261 in vitro synergistic effects between the SK1-specific inhibitor SK1-I and standard chemotherapeutics,

262 ortantly, disruption of JNK signaling with a specific inhibitor (SP600125) or knockdown technology (L

263 Inhibition of either signaling pathway with specific inhibitor suppressed T63-induced RUNX2 expressi

264 information may also aid efforts to develop specific inhibitors targeting this essential viral enzym

265 modulin-dependent protein kinase II (CaMKII) specific inhibitor tatCN21 peptide.

266 ed many SCF ligases, or conversely, a highly specific inhibitor that discriminated between even the c

267 vel insights into the potent bacterial betaG-specific inhibitor that would allow this inhibitor to be

268 an increased interest in the development of specific inhibitors that can provide potential novel pha

269 ew clinical trials have been initiated using specific inhibitors that inhibit novel kinase targets, d

270 ic regulators identified several bromodomain-specific inhibitors that promote differentiation and ena

271 i) mice deficient for calpastatin, a calpain-specific inhibitor, thus enhancing calpain activity (Syn

272 owski and colleagues identified a novel CDK7-specific inhibitor, THZ1, that hinders proliferation in

273 Using specific inhibitors to block SLC1A5 and CD98 function, w

274 d assessed the potential use of PI3K isoform-specific inhibitors to favorably condition CD8(+) T cell

275 ted exclusively mTORC1 due to the paucity of specific inhibitors to S6K1.

276 MSCs were treated with specific inhibitors to suppress PGE2 secretion, and prol

277 d that can be explored to produce potent and specific inhibitors towards VRK1 and VRK2.

278 ment of Mer(high) patient cells with the Mer-specific inhibitor UNC-569 in vivo delayed leukemia onse

279 e extended our efforts to identify PI3Kalpha-specific inhibitors using PI3Kalpha crystal structures t

280 arget sensitivity was achieved with the BCL2-specific inhibitor venetoclax (ABT-199).

281 A MEK1/2-specific inhibitor was found to block CSF1-induced JDP2

282 Using specific inhibitors, we demonstrated that both steps wer

283 Using specific inhibitors, we find that nuclear movement and a

284 Using DREAM-null platelets and PI3K isoform-specific inhibitors, we observed that platelet DREAM is

285 Furthermore, using novel RIPK2-specific inhibitors, we show that cellular recruitment i

286 By using genetically modified stem cells and specific inhibitors, we show that embryogenesis of ESC-

287 Using specific inhibitors, we showed that CCHFV NSs induces ap

288 entification of the first orally active JAK3 specific inhibitor, which achieves JAK isoform specifici

289 These specific inhibitors, which are active in cell culture mo

290 uctural insights into their interaction with specific inhibitors will contribute to the development o

291 These exquisitely specific inhibitors will facilitate the dissection of Ep

292 stoyl lysine compound, TM, as a potent SIRT2-specific inhibitor with a broad anticancer effect in var

293 lung cancer, coadministration of a PI3Kdelta-specific inhibitor with a tumor-specific vaccine decreas

294 data present the first neutrophil exocytosis-specific inhibitor with in vivo anti-inflammatory activi

295 nol is identified as a kind of non-toxic CSC specific inhibitors with significant therapeutic potenti

296 Together, these findings indicate that specific inhibitors with the ability to block pathologic

297 nt in the family of PHDK enzymes and a PDHK1 specific inhibitor would therefore have anti-cancer acti

298 izes Snail1 by inducing Dub3 expression, the specific inhibitor WP1130 binds to Dub3 and inhibits the

299 mulated by Chiffon and inhibited by the Cdc7-specific inhibitor XL413.

300 hat this could be antagonized with the Cat L-specific inhibitor Z-FY-CHO.